Epidemiology shows that approximately 30–40% of non-small cell lung cancer (NSCLC) patients have epidermal growth factor receptor (EGFR) mutations (Dizon et al., 2016). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.